natgillin/translations-raw huggingface dataset:
Dermal assessment
Procjena kože
Dermal toxicity
Toksični učinci na kožu
Dermatitis
akne/akneiformni dermatitis
Dermatitis
dermatitis
Dermatitis
često
Dermatitis (including allergic and atopic dermatitis)
dermatitis (uključujući alergijski i atopijski dermatitis)
Dermatitis (including contact, atopic, and diaper rash), Heat rash, Rubella-like rash‡, Urticaria, Viral exanthema, Eczema, Erythema
dermatitis (uključujući kontaktni, atopijski i pelenski osip), osip od vrućine, osip sličan rubeli‡, urtikarija, virusni egzantem, ekcem, eritem
dermatitis (including eczema),
dermatitis (uključujući ekcem),
Dermatitis acneiform
akneiformni dermatitis
Dermatitis acneiform Rash1,2 Erythema Pruritus Dry skin
Akneiformni dermatitis Osip1,2 Eritem Svrbež
Dermatitis allergic
alergijski dermatitis
Dermatitis allergic Rash
Alergijski dermatitis Osip
dermatitis allergic, periorbital oedema, dermatitis contact, erythema, rash, hair colour changes, hair texture abnormal, hypertrichosis, madarosis
alergijski dermatitis, periorbitalni edem, kontaktni dermatitis, eritem, osip, promjena boje dlaka, abnormalna tekstura dlaka, hipertrihoza, madaroza
Dermatitis and eczema
Dermatitis i ekcem
Dermatitis atopic, eczema
atopijski dermatitis, ekcem
dermatitis contact
kontaktni dermatitis
dermatitis contact, dermatosis, ecchymosis, lichenoid keratosis, night sweats,
kontaktni dermatitis, dermatoza, ekhimoza, lihenoidna keratoza, noćno znojenje, bolna koža,
Dermatitis contact, erythema, rash, urticaria
Kontaktni dermatitis, eritem, osip, urtikarija
dermatitis contact, hypertrichosis
kontaktni dermatitis, hipertrihoza.
dermatitis contact, skin burning sensation, dry skin
kontaktni dermatitis, osjećaj žarenja kože, suhoća kože
Dermatitis exfoliative
eksfolijativni dermatitis
dermatitis exfoliative, alopecia, rash maculo-papular, pruritus, erythema
eksfolijativni dermatitis, alopecija, makulopapulozni osip, pruritus, eritem
Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more feet during the study with the number and frequency of observations increasing with increasing dose.
Za vrijeme provođenja studije uočeno je da su lezije uzrokovane dermatitisom uglavnom sekundarne pri stvaranju interdigitalnih furunkuloza na jednom ili više ekstremiteta, s time da se broj i učestalost lezija povećava sa povećavanjem doze.
Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more feet during the study, with the number and frequency of observations increasing with increasing dose.
Za vrijeme provođenja studije uočeno je da su lezije uzrokovane dermatitisom uglavnom sekundarne pri stvaranju interdigitalnih furunkuloza na jednom ili više ekstremiteta, s time da se broj i učestalost lezija povećava s povećavanjem doze.
Dermatitis Rash
dermatitis osip
Dermatitis Urticaria Rash pruritic* Pruritus*
dermatitis urtikarija pruritični osip* pruritus
Dermatitis,
Vrlo često
Dermatitis, eczema, erythema, hyperhidrosis, night sweats, oedema peripheral, psoriasis, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, skin lesion
dermatitis, ekcem, eritem, hiperhidroza, noćno znojenje, periferni edem, psorijaza, eritematozni osip, makularni osip, makulopapularni osip, papularni osip, osip koji svrbi, lezije kože
dermatitis, erythema
dermatitis, eritem
dermatitis, erythema, vitiligo, urticaria, eczemad, alopecia, night sweats, dry skin
dermatitis, eritem, vitiligo, urtikarija, ekcemd, alopecija, noćno znojenje, suha koža
Dermatitis, night sweats, pruritus, rash, pruritus generalised, dry skin
dermatitis, noćno znojenje, pruritus, osip, generalizirani pruritus, suha koža
dermatitis, photosensitivity
dermatitis, fotoosjetljivost
dermatitis, pruritus, rash urticaria
dermatitis, pruritus, osip, urtikarija
Dermatitis; Rash erythematous (G3/4: <1%);
dermatitis eritematozni osip (G 3/4:
DermatitisC, pruritusC,
dermatitisC, pruritusC, urtikarijaC
Dermatofibrosarcoma protuberans (DFSP).
Dermatofibrosarkoma protuberans (DFSP).
Dermatologic evaluation should be performed on a systematic and regular basis, whenever VFEND is continued despite the occurrence of phototoxicity-related lesions, to allow early detection and management of premalignant lesions.
Dermatološku procjenu treba provoditi sistematično i redovito, kad god se nastavlja primjena lijeka VFEND unatoč pojavi lezija povezanih s fototoksičnošću, kako bi se omogućila rana detekcija i liječenje predmalignih lezija.
Dermatologic evaluation should be performed on a systematic and regular basis, whenever Voriconazole Accord is continued despite the occurrence of phototoxicity-related lesions, to allow early detection and management of premalignant lesions.
Dermatološku procjenu treba provoditi sistematično i redovito, kad god se nastavlja primjena lijeka Voriconazole Accord unatoč pojavi lezija povezanih s fototoksičnošću kako bi se omogućila rana detekcija i liječenje predmalignih lezija.
Dermatologic evaluation should be performed on a systematic and regular basis, whenever Voriconazole Hospira is continued despite the occurrence of phototoxicity-related lesions, to allow early detection and management of premalignant lesions.
Dermatološku procjenu treba provoditi sistematično i redovito, kad god se nastavlja primjena lijeka Vorikonazol Hospira unatoč pojavi lezija povezanih s fototoksičnošću, kako bi se omogućila rana detekcija i liječenje predmalignih lezija.
Dermatologic reactions (f)
Dermatološke reakcije (f)
Dermatologic related reactions, a pharmacologic effect observed with epidermal growth factor receptor (EGFR) inhibitors, are experienced with nearly all patients (approximately 90%) treated with Vectibix.
Dermatološke reakcije vezane uz farmakološki učinak koji je uočen pri liječenju inhibitorima receptora epidermalnog čimbenika rasta (EGFR) primijećene su kod gotovo svih bolesnika (približno 90%) liječenih lijekom Vectibix.
Dermatological
Dermatološki
Dermatological adverse reactions
Kožne nuspojave
Dermatological reactions
Kožne reakcije
Dermatological reactions (including nail effects), observed in patients treated with Vectibix or other EGFR inhibitors, are known to be associated with the pharmacologic effects of therapy (with cross- reference to sections 4.2 and 4.8).
Poznato je da su dermatološke reakcije (uključujući učinke na nokte) opažene kod bolesnika liječenih lijekom Vectibix ili drugim inhibitorima EGFR-a povezane s farmakološkim učincima terapije (unakrsna referenca na dio 4.2. i 4.8).
Dermatologist Static Global Assessment.
Dermatologist Static Global Assessment (Dermatološka statička globalna procjena).
Dermatophytosis
dermatofitoza
Derzsy’s disease is a similar infection caused by the closely related virus, goose parvovirus.
Derzsy bolest je bolest slična infekciji uzrokovana usko povezanim virusom, parvovirusom guske.
Desacetyl-diltiazem AUC ↑165%
Desacetil-diltiazem AUC ↑165
Desacetyl-diltiazem Cmax ↑172%
Desacetil-diltiazem Cmax ↑172
Desacetyl-diltiazem Cmax ↑172%
Dezacetil-diltiazem Cmax ↑172
Desacetyl-diltiazem Cmin ↑121%
Desacetil-diltiazem Cmin ↑121
Desacetyl-diltiazem Cmin ↑121%
Dezacetil-diltiazem Cmin ↑121
Descending colon wall
Stijenka silaznog debelog crijeva
Descovy 200 mg/10 mg film-coated tablets
Descovy 200 mg/10 mg filmom obloţene tablete
Descovy 200 mg/10 mg film-coated tablets emtricitabine/tenofovir alafenamide
Descovy 200 mg/10 mg filmom obloţene tablete emtricitabin/tenofoviralafenamid
Descovy 200 mg/25 mg film-coated tablets
Descovy 200 mg/25 mg filmom obloţene tablete
Descovy 200 mg/25 mg film-coated tablets emtricitabine/tenofovir alafenamide
Descovy 200 mg/25 mg filmom obloţene tablete emtricitabin/tenofoviralafenamid
Descovy 200/10 mg once daily
Descovy 200/10 mg jedanput na dan
Descovy 200/25 mg once daily
Descovy 200/25 mg jedanput na dan
Descovy blocks the action of the reverse transcriptase enzyme, which is essential for the virus to multiply.
Descovy koči djelovanje enzima reverzne transkriptaze koji je nuţan za umnaţanje virusa.
Descovy can cause dizziness.
Descovy moţe uzrokovati omaglicu.
Descovy contains two active substances:
Descovy sadrţi dvije djelatne tvari:
Descovy film-coated tablets are blue, rectangular-shaped tablets, debossed on one side with “GSI” and the number “225” on the other side of the tablet.
Descovy filmom obloţene tablete su plave tablete pravokutnog oblika, s utisnutom oznakom „GSI“ na jednoj strani i „225“ na drugoj strani tablete.
Descovy film-coated tablets are grey, rectangular-shaped tablets, debossed on one side with “GSI” and the number “210” on the other side of the tablet.
Descovy filmom obloţene tablete su sive tablete pravokutnog oblika, s utisnutom oznakom „GSI“ na jednoj strani i „210“ na drugoj strani tablete.
Descovy has not been studied in patients with severe hepatic impairment (Child-Pugh Class C); therefore, Descovy is not recommended for use in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Lijek Descovy nije ispitan u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) te se stoga primjena lijeka Descovy ne preporučuje u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dijelove 4.4 i 5.2).
Descovy in combination with other medicines is for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults and adolescents 12 years of age and older, who weigh at least 35 kg.
Descovy se u kombinaciji s drugim lijekovima primjenjuje za lijeĉenje infekcije virusom humane imunodeficijencije 1 (HIV-1) u odraslih i adolescenata u dobi od 12 godina i starijih, koji imaju tjelesnu teţinu od najmanje 35 kg.
Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) (see sections 4.2 and 5.1).
Lijek Descovy je indiciran u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih osoba i adolescenata (u dobi od 12 godina i starijih, s tjelesnom teţinom od najmanje 35 kg) zaraţenih virusom humane imunodeficijencije tipa 1 (HIV-1) (vidjeti dijelove 4.2 i 5.1).
Descovy may interact with other medicines.
Descovy moţe biti u interakciji s drugim lijekovima.
Descovy should be administered as shown in Table 1.
Descovy se primjenjuje kako je prikazano u Tablici 1.
Descovy should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see sections 5.1 and 5.2).
Potrebno je prekinuti liječenje lijekom Descovy u bolesnika u kojih procijenjeni CrCl tijekom liječenja opada na vrijednosti ispod 30 ml/min (vidjeti dijelove 5.1 i 5.2).
Descovy should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Descovy se smije primjenjivati tijekom trudnoće samo ako moguća korist opravdava mogući rizik za fetus.
Descovy should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), emtricitabine, lamivudine or adefovir dipivoxil.
Descovy se ne smije primjenjivati istodobno s lijekovima koji sadrţavaju tenofovirdizoproksil (u obliku fumarata), emtricitabin, lamivudin ili adefovirdipivoksil.
Descovy should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), lamivudine or adefovir dipivoxil used for the treatment of HBV infection.
Descovy se ne smije primjenjivati istodobno s lijekovima koji sadrţavaju tenofovirdizoproksil (u obliku fumarata), lamivudin ili adefovirdipivoksil koji se primjenjuju za liječenje infekcije HBV-om.
Descovy should not be initiated in patients with estimated CrCl < 30 mL/min as there are limited data available regarding the use of Descovy in this population (see sections 5.1 and 5.2).
Primjena lijeka Descovy se ne smije započeti u bolesnika s procijenjenim CrCl < 30 ml/min budući da su dostupni ograničeni podaci o primjeni lijeka Descovy u ovoj populaciji (vidjeti dijelove 5.1 i 5.2).
Description and management of infections, dizziness and confusion, tumor lysis syndrome, allergic reactions, hepatic disorders, cardiac failure and interstitial lung disease o
opis i zbrinjavanje infekcija, omaglice i konfuzije, sindroma lize tumora, alergijskih reakcija i poremećaja funkcije jetre, zatajenja srca i intersticijske bolesti pluća
Description and management of neutropenia and thrombocytopenia including incidence rates from clinical trials
opis i zbrinjavanje neutropenije i trombocitopenije, uključujući stope incidencije iz kliničkih ispitivanja
Description and management of thromboembolic risk including incidence rates from clinical trials and post-marketing experience
opis i zbrinjavanje tromboembolijskog rizika, uključujući stope incidencije iz kliničkih ispitivanja i iskustva nakon stavljanja lijeka u promet
Description and management of venous and arterial thromboembolic events, cardiovascular events, and peripheral neuropathy
opis i zbrinjavanje venskih i arterijskih tromboembolijskih događaja, kardiovaskularnih događaja i periferne neuropatije
Description of available deferasirox formulations
opis dostupnih formulacija deferasiroksa
Description of cardiorespiratory disorders including incidence rates from clinical trials
Opis kardiorespiratornih poremećaja, uključujući stope incidencije u kliničkim ispitivanjima
Description of MRI protocols for baseline, routine screening and in case of PML suspicion
Opis MR protokola za početni, rutinski probir i u slučaju sumnje na PML
Description of post injection syndrome
Opis postinjekcijskog sindroma
Description of reconstitution and proper administration technique
Opis pripreme i ispravne tehnike primjene
Description of risk of tumor flare reaction in MCL patients
opis rizika od reakcije razbuktavanja tumora u bolesnika s limfomom plaštenih stanica
Description of selected Adverse Drug Reactions (ADRs)
Opis odabranih nuspojava lijeka
Description of selected adverse events
Opis odabranih štetnih događaja
Description of selected adverse reactions
Opis odabarnih nuspojava
Description of selected adverse reactions
Opis ostalih odabranih nuspojava
Description of selected adverse reactions
Opis pojedinih nuspojava
Description of selected adverse reactions
Tablični popis nuspojava
Description of selected adverse reactions Aseptic meningitis
Opis odabranih nuspojava Aseptički meningitis
Description of selected adverse reactions Class effects:
Opis odabranih nuspojava Učinci klase:
Description of selected adverse reactions Class effects:
Opis odabranih nuspojava Učinci po skupinama:
Description of selected adverse reactions Dapagliflozin plus metformin Hypoglycaemia
Opis odabranih nuspojava Dapagliflozin u kombinaciji s metforminom Hipoglikemija
Description of selected adverse reactions Drug hypersensitivity reactions:
Opis odabranih nuspojava Reakcije preosjetljivosti na lijek:
Description of selected adverse reactions for adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis odabranih nuspojava za adjuvantno liječenje za docetakselom 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima
Description of selected adverse reactions for adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis odabranih nuspojava za adjuvantno liječenje za Docetaxel 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima
Description of selected adverse reactions for adjuvant therapy with Docetaxel Winthrop 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis odabranih nuspojava za adjuvantno liječenje za Docetaxel Winthrop 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima
Description of selected adverse reactions for adjuvant therapy with Taxotere 75 mg/m2 in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis odabranih nuspojava za adjuvantno liječenje za TAXOTERE 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima
Description of selected adverse reactions for adjuvant therapy with TAXOTERE 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis odabranih nuspojava za adjuvantno liječenje za TAXOTERE 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima
Description of selected adverse reactions for more details.
Opis odabranih nuspojava za detaljnije informacije.
Description of selected adverse reactions Herpes zoster virus reactivation Multiple Myeloma
Opis odabranih nuspojava Reaktivacija virusa herpes zoster Multipli mijelom
Description of selected adverse reactions in breast cancer for adjuvant therapy with TAXOTERE 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis odabranih nuspojava za adjuvantno liječenje za TAXOTERE 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima
Description of selected adverse reactions in breast cancer for Docetaxel 100 mg/m2 in combination with trastuzumab
Opis odabranih nuspojava kod karcinoma dojke za Docetaxel 100 mg/m² u kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for Docetaxel 100 mg/m2 single agent
Opis odabranih nuspojava kod karcinoma dojke za Docetaxel 100 mg/m2 u monoterapiji
Description of selected adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m2 in combination with trastuzumab
Opis odabranih nuspojava kod karcinoma dojke za Docetaxel Winthrop 100 mg/m² u kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m2 single agent
Opis odabranih nuspojava kod karcinoma dojke za Docetaxel Winthrop 100 mg/m2 u monoterapiji
Description of selected adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m² in combination with trastuzumab
Opis odabranih nuspojava kod karcinoma dojke za Docetaxel Winthrop 100 mg/m² u kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m² single agent
Opis odabranih nuspojava kod karcinoma dojke za Docetaxel Winthrop 100 mg/m2 u monoterapiji
Description of selected adverse reactions in breast cancer for Taxespira 100 mg/m2 in combination with trastuzumab
Opis odabranih nuspojava kod karcinoma dojke za Taxespira 100 mg/m² u kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for Taxespira 100 mg/m2 single agent
Opis odabranih nuspojava kod karcinoma dojke za Taxespira 100 mg/m2 u monoterapiji
Description of selected adverse reactions in breast cancer for Taxotere 100 mg/m2 in combination with trastuzumab
Opis odabranih nuspojava kod karcinoma dojke za TAXOTERE 100 mg/m² u kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for TAXOTERE 100 mg/m2 single agent
Opis odabranih nuspojava kod karcinoma dojke za TAXOTERE 100 mg/m2 u monoterapiji
Description of selected adverse reactions in breast cancer for TAXOTERE 100 mg/m² single agent
Opis odabranih nuspojava kod karcinoma dojke za TAXOTERE 100 mg/m2 u monoterapiji
Description of selected adverse reactions in children and adolescents
Opis odabranih nuspojava u djece i adolescenata
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis odabranih nuspojava za docetaksel 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis odabranih nuspojava za Docetaxel 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Description of selected adverse reactions in gastric adenocarcinoma cancer for DOCETAXEL KABI 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis odabranih nuspojava za DOCETAXEL KABI 75 mg/m² u kombinaciji s cisplatinom i 5- fluorouracilom u terapiji adenokarcinoma želuca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel Winthrop 75 mg/m2 in combination with ciplatin and 5-fluorouracil
Opis odabranih nuspojava za Docetaxel Winthrop 75 mg/m² u kombinaciji s cisplatinom i 5- fluorouracilom u terapiji adenokarcinoma želuca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel Winthrop 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis odabranih nuspojava za Docetaxel Winthrop 75 mg/m² u kombinaciji s cisplatinom i 5- fluorouracilom u terapiji adenokarcinoma želuca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel Winthrop 75 mg/m² in combination with cisplatin and 5-fluorouracil
Opis odabranih nuspojava za Docetaxel Winthrop 75 mg/m² u kombinaciji s cisplatinom i 5- fluorouracilom u terapiji adenokarcinoma želuca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Taxespira 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis odabranih nuspojava za Taxespira 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Description of selected adverse reactions in gastric adenocarcinoma cancer for TAXOTERE 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis odabranih nuspojava za TAXOTERE 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Description of selected adverse reactions Inhibitor Development
Opis izabranih nuspojava Razvoj inhibitora
Description of selected adverse reactions Mitochondrial toxicity
Opis odabranih nuspojava Mitohondrijska toksičnost
Description of selected adverse reactions observed with other PDE5 inhibitors
Opis odabranih nuspojava opaženih s drugim inhibitorima PDE5
Description of selected adverse reactions observed with Zutectra
Prikaz odabranih nuspojava opaženih s lijekom Zutectra
Description of selected adverse reactions pertinent to allergic asthma and CSU indications
Opis sigurnosnih odabranih nuspojava koji su važni za indikacije alergijske astme i KSU-a
Description of selected adverse reactions).
Opis odabranih nuspojava).
Description of selected of adverse reactions for adjuvant therapy with Docetaxel Winthrop 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis odabranih nuspojava za adjuvantno liječenje za Docetaxel Winthrop 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima
Description of the administration procedures of BLINCYTO
Opis postupaka primjene lijeka BLINCYTO.
Description of the administration procedures of BLINCYTO and how to reduce the risk of ME while using the infusion pump.
Opis postupaka primjene lijeka BLINCYTO i kako smanjiti rizik od medikacijskih pogreški tijekom primjene infuzijske pumpe.
Description of the administration system
Opis sustava za primjenu
Description of the key differences between Kadcyla and Herceptin in relation to indication, dose, administration and packaging differences.
Opis ključnih razlika između lijekova Kadcyla i Herceptin s obzirom na indikaciju, dozu, primjenu i razlike u pakiranju.